Congresses
header logo

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from
Choose a Country ▼

LOOK FOR
REPATHA® AND AMGEN
AT MAJOR CARDIOLOGY
CONGRESSES

Amgen is excited to participate in
ESC Congress 2021 – The Digital Experience

For the second year running, ESC Congress is being held entirely online, giving cardiovascular professionals unparalleled access to the latest clinical updates and cutting-edge science.
Throughout the Congress, Amgen and Repatha® are hosting a range of activities designed to ESCalate the management of your post-MI patients through early, intensive LDL-C lowering.
Step inside our Virtual Booth and explore the next level of post-MI care with Repatha®
ENTER
Visit the Medical Meeting Point – your customised scientific platform for congress presentations, webinars and more.
Look out for the late-breaking science on Friday 27 August @ 10:30 CEST and check out abstract and oral presentations on Repatha® in real-world use.
And be sure to check out our two unmissable symposia, which are available live and on-demand after the Congress.
  • Friday 27 August @ 19:00–19:30 - 6 Years On, What Have We Learned from Real-World Use of PCSK9i?
    - Introduction – Mikhail Kosiborod (Chair)
    - The European experience: SWEDEHEART & AIFA registries (Marcello Arca, Italy)
    - The European experience: HEYMANS study (Kausik Ray, UK)
    - The North American experience: GOULD (Mikhail Kosiborod, USA)
    - Live panel discussion
  • Monday 30 August @ 19:00–19:30 - LDL-C Management in ACS: Time to Act
    - Introduction – Derek Connolly (Chair)
    - Time to act: Stabilising the vulnerable plaque with PCSK9i (Steve Nicholls, Australia)
    - Time to act: When should our ACS patients reach their LDL-C goal? (Gilles Montalescot, France)
    - Live panel discussion

*
25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CI = Confidence interval; CV = Cardiovascular; ESC = European Society of Cardiology; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.
  1. Gencer B, et al. JAMA Cardiol. 2020;5(8):1-6.

By clicking the 'DOWNLOAD' button below you will immediately begin downloading the Reporting Systems Appendix
Return to previous page DOWNLOAD